Aileron Therapeutics Inc

NASDAQ:ALRN   3:59:56 PM EDT
1.12
+0.06 (+5.19%)
Regulatory, Other Pre-Announcement

Aileron Therapeutics Provides Business Update And Outlines 2021 Strategic Priorities

Published: 12/21/2020 16:26 GMT
Aileron Therapeutics Inc (ALRN) - Aileron Therapeutics Provides Business Update and Outlines 2021 Strategic Priorities.
Aileron Therapeutics - Anticipated Milestones Include Reporting Initial Results From Phase 1b Nsclc Clinical Trial in Q4 2021.
Aileron Therapeutics Inc - in 2021, Plans to Report Additional Results From Ongoing Phase 1b Clinical Trial in Patients With Sclc.
Aileron Therapeutics - Due to Covid-19-related Delays, Updating Guidance on Readout of Healthy Volunteer Study From Q2 of 2021 to Mid-2021.